Wafik S. El-Deiry, Director of Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, shared a post on LinkedIn:
“My welcoming comments at Inaugural National Caris Life Sciences Precision Oncology Alliance Member Meeting at Brown University highlighted some of the impact of the Brown-Caris POA collaboration going back to 2019.
Dr. David Spetzler, President at Caris Life Sciences speaks about advances in precision medicine at Inaugural National Caris Precision Oncology Alliance Member Meeting at Brown University.
‘There are 300 copies of the human genome in 1 ng of DNA.’
‘Can we explain it in knowledge in biology’.
The future is in precision prevention.
Dr. James Hamrick, SVP of Medical Affairs and Chairman of the Precision Oncology Alliance (POA) at Caris Life Sciences speaks about how collaboration with the Caris POA empowers your research at Brown University.
Group photo of in person attendees this morning at the Inaugural National Caris Precision Oncology Alliance Member Meeting at Brown University Caris Life Sciences.
Dr. Hina Khan speaks about lung cancer screening in Rhode Island at the Inaugural National Caris Precision Oncology Alliance Member Meeting at Brown University Caris Life Sciences. Dr. Khan shared impressive impact on lung cancer screening through intervention within underserved communities.
Dr. Jon Steingrimsson at Brown University School of Public Health speaks about updating the effectiveness of lung cancer screening at the Inaugural National Caris Precision Oncology Alliance Member Meeting at Brown University Caris Life Sciences.
Dr. Sana Raoof, MD-PhD speaks about ‘Advancing Evidence Generation on Multi Cancer Early Detection Technologies through Novel Statistical Methods and Modeling, Adaptive Trial Designs and Real-World Evidence’ at the Inaugural National Caris Precision Oncology Alliance Member Meeting at Brown University Caris Life Sciences.
She made compelling arguments about the need to pay much more attention to cancer screening to really impact long-term on people’s lives.
‘Only 14% of cancers in the US are detected by screening.’
She spoke about the Caris x Brown MCED study with an amazing team at the two Institutions.
She highlighted the importance of collaboration and the strengths of the strategy used by the Caris x Brown team.
Dr. Sana Raoof, MD-PhD moderates Panel on Cancer Screening including Donna Rivera, PharmD, MSc, Executive Vice President, Clinical Evidence Modernization and Larry Kessler, Professor, Health Systems and Population Health, University of Washington, faculty from Brown Department of Biostatistics: Constantine Gatsonis, PhD, Henry Ledyard Goddard University Professor; Jon Steingrimsson, PhD, Associate Professor; Thomas Trikalinos, Director of the Center for Evidence Synthesis in Health, Professor of Health Services, Policy and Practice and David Spetzler, President at Caris Life Sciences at the Inaugural National Caris Precision Oncology Alliance Member Meeting at Brown University Caris Life Sciences.
Dr. Constantine Gatsonis, PhD, Henry Ledyard Goddard University Professor at Brown University School of Public Health made some important comments in the panel on cancer screening at the at the Inaugural National Caris Precision Oncology Alliance Member Meeting at Brown University Caris Life Sciences.
‘Screening has always been contentious’
‘Multicancer screening even more’
‘How do we develop consensus?’
‘There is a hardship of false + in population screening’
‘MCED’s are an entirely new paradigm—needs studies that show impact’.
Dr. David Spetzler, President at Caris Life Sciences made some important comments in the panel on cancer screening at the at the Inaugural National Caris Precision Oncology Alliance Member Meeting at Brown University Caris Life Sciences
He spoke about ‘multiplicity and the hypersegmentation problem’ as causing ‘the risk of false discovery to go up’ and driving up the sample size.
He spoke about cofounders, the need to address the complexity of biology.
Dr Spetzler also said ‘unnecessary interventions need to be minimized’.
Dr. Ece Uzun, PhD, MS, FAMIA speaks about ‘Multimodal Deep Learning Model for Cancer Recurrence Prediction Using Genomic and Clinical Data’ at the at the Inaugural National Caris Precision Oncology Alliance Member Meeting at Brown University Caris Life Sciences
She spoke about prediction of glioma recurrence using the LUNAR model, TCGA and the GLASS Consortium.
‘Deep Learning models have great potential for predicting glioma recurrence.’
Dr. Rebecca Hubbard, PhD, Brown University School of Public Health speaks about ‘Data Science Collaborative for Real-World Evidence in Cancer Therapeutics’ at the Inaugural National Caris Precision Oncology Alliance Member Meeting at Brown University Caris Life Sciences
She mentioned that an issue with RWD is that it is not pre-specified for the use.
FDA has raised the concept of ‘fit for use’
Dr. Hubbard spoke about target trial emulation framework for comparative effectiveness of cancer therapeutics research. This is an observational study design that matches design elements of a prospective RCT.
However recent literature published in JAMA Network suggests limitations in current usage of the approach including missing criteria in RWD such as ECOG performance status or other inclusion/exclusion criteria.
Strategies for dealing with these issues were discussed including dealing with inevitable biases.
Other articles featuring Wafik S. El-Deiry on OncoDaily.
